We report on the exploratory immunogenomic biomarker analysis of tumor samples from children with refractory/relapsed cancers before treatment with the anti-PD-L1 antibody, atezolizumab, in the iMATRIX-atezo study4. Here, CD274 is linked to neoplasm.